115 lines
40 KiB
Text
115 lines
40 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548114">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548114/?report=reader">
|
|
<meta name="ncbi_pagename" content="Rosiglitazone - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Rosiglitazone - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Ropinirole/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Rosuvastatin/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Rosiglitazone">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2018/06/06">
|
|
<meta name="citation_pmid" content="31643444">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548114/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Rosiglitazone">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2018/06/06">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548114/">
|
|
<meta name="description" content="Rosiglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Rosiglitazone has been linked to rare instances of acute liver injury.">
|
|
<meta name="og:title" content="Rosiglitazone">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Rosiglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Rosiglitazone has been linked to rare instances of acute liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548114/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Rosiglitazone/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548114/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C1BE37D7F390100000000002E0021.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548114/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Ropinirole/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Rosiglitazone</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Rosuvastatin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548114/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548114/&text=Rosiglitazone"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548114/?report=classic">Switch to classic view</a><a href="/books/NBK548114/pdf/Bookshelf_NBK548114.pdf">PDF (90K)</a><a href="/books/NBK548114/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548114%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C1BE37D7F390100000000002E0021.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548114_"><span class="title" itemprop="name">Rosiglitazone</span></h1><p class="fm-aai"><a href="#_NBK548114_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Rosiglitazone.OVERVIEW"><h2 id="_Rosiglitazone_OVERVIEW_">OVERVIEW</h2><div id="Rosiglitazone.Introduction"><h3>Introduction</h3><p>Rosiglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Rosiglitazone has been linked to rare instances of acute liver injury.</p></div><div id="Rosiglitazone.Background"><h3>Background</h3><p>Rosiglitazone (roe" si gli' ta zone) an insulin sensitizing agent that improves glucose control in patients with type 2 diabetes. Like other thiazolidinediones, it is thought to act by engagement of PPAR-γ receptors which induce multiple genes involved in glucose and fatty acid metabolism. In clinical trials, rosiglitazone was found to lower blood glucose and HbA1c levels and had additive effects with the sulfonylureas and metformin. Rosiglitazone was approved for use in the United States in 1999. While the initial thiazolidinedione – troglitazone – had been associated with high rates of serum aminotransferase elevations and multiple reports of severe liver injury and death from acute liver failure, rosiglitazone was associated with a lower rate of ALT elevations and with only rare instances of clinically apparent liver injury. Rosiglitazone is approved as an adjunct to diet and exercise in the glycemic control of patients with type 2 diabetes. Rosiglitazone is available as 2 and 4 mg tablets generically and under the brand name Avandia and the usual recommended dosage is 4 to 8 mg daily in two divided doses. Rosiglitazone is used as monotherapy as well as in combination with metformin, sulfonylureas or insulin. In 2010, the FDA published a drug safety alert concerning the cardiovascular risks of rosiglitazone and the drug has been withdrawn in many countries of the world, because of these potential long term adverse effects. In the United States, it remains available but is recommended only for patients who are unable to achieve glycemic control with other diabetes medications.</p></div><div id="Rosiglitazone.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In contrast to troglitazone, rosiglitazone is not associated with an increased frequency of aminotransferase elevations during therapy. In clinical trials, ALT elevations above 3 times the ULN occurred in only 0.25% of patients on rosiglitazone, compared to 0.25% of placebo recipients (and 1.9% of troglitazone recipients in similar studies). In addition, clinically apparent liver injury attributed to rosiglitazone is very rare, fewer than a dozen cases having been described in the literature despite extensive use of this agent. The liver injury usually arises between 1 and 12 weeks after starting therapy (thus, a shorter latency than typically occurs with troglitazone) and all patterns of serum enzyme elevations have been described including hepatocellular, cholestatic and mixed. Allergic phenomena are rare and autoantibodies have not been typically present. Fatal instances have been reported usually in cases with a hepatocellular pattern of injury. In most instances, recovery is complete within 1 to 2 months.</p><p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p></div><div id="Rosiglitazone.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of liver injury due to rosiglitazone is not known, but the general pattern and course differs somewhat from troglitazone and it is unlikely that the thiazolidinediones share a single mechanism for liver injury.</p></div><div id="Rosiglitazone.Outcome_and_Management"><h3>Outcome and Management</h3><p>The liver injury from rosiglitazone is usually reversed with stopping the medication. Fatal cases of rosiglitazone associated liver injury have been reported, but most cases were self-limiting. Chronic liver disease and vanishing bile duct syndrome have not been reported with rosiglitazone therapy. There is at least some degree of cross sensitivity to the liver injury caused by the different thiazolidinediones, so that patients with rosiglitazone hepatotoxicity should avoid use of pioglitazone.</p><p>References to the safety and hepatotoxicity of rosiglitazone are given together with references to pioglitazone and troglitazone in the Overview section on the Thiazolidinediones (updated June 2018).</p><p>Drug Class: <a href="/books/n/livertox/Antidiabetic/?report=reader">Antidiabetic Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/Thiazolidinediones/?report=reader">Thiazolidinediones</a>: <a href="/books/n/livertox/Pioglitazone/?report=reader">Pioglitazone</a>, <a href="/books/n/livertox/Troglitazone/?report=reader">Troglitazone</a></p></div></div><div id="Rosiglitazone.CASE_REPORT"><h2 id="_Rosiglitazone_CASE_REPORT_">CASE REPORT</h2><div id="Rosiglitazone.Case_1._Acute_hepatitis_af"><h3>Case 1. Acute hepatitis after 8 days of rosiglitazone therapy.</h3><p>[Modified from: Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132: 121-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/10644273" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed Citation</a>]</p><p>A 61 year old man with diabetes was started on rosiglitazone and developed symptoms of nausea and abdominal pain within 8 days and jaundice within 2 weeks. The patient had poorly controlled diabetes for which he took sulfonylureas and metformin without adequate control. He was tried on troglitazone therapy, but it was discontinued after 8 days because of nausea and upset stomach. After failure to tolerate repaglinide because of nausea and dizziness, he was started on rosiglitazone. Eight days later he developed anorexia, nausea and abdominal pain and subsequently noted onset of dark urine and fever. His liver test results had been normal before starting rosiglitazone, but 11 days later he had marked elevations in serum aminotransferase levels and jaundice (Table). Rosiglitazone was stopped and he began to improve. Tests for hepatitis A, B and C were negative as were autoantibodies. Ultrasonography showed no evidence of gallstones or biliary tract disease. He also had chronic obstructive pulmonary disease and a remote history of alcoholism. After a week in the hospital, he was discharged. Subsequent testing showed a slow improvement in his liver tests. Serum aminotransferase levels were normal two months later.</p><div id="Rosiglitazone.Key_Points"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figRosiglitazoneT1"><a href="/books/NBK548114/table/Rosiglitazone.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figRosiglitazoneT1" rid-ob="figobRosiglitazoneT1"><img class="small-thumb" src="/books/NBK548114/table/Rosiglitazone.T1/?report=thumb" src-large="/books/NBK548114/table/Rosiglitazone.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Rosiglitazone.T1"><a href="/books/NBK548114/table/Rosiglitazone.T1/?report=objectonly" target="object" rid-ob="figobRosiglitazoneT1">Table</a></h4></div></div></div><div id="Rosiglitazone.Laboratory_Values"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figRosiglitazoneT2"><a href="/books/NBK548114/table/Rosiglitazone.T2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figRosiglitazoneT2" rid-ob="figobRosiglitazoneT2"><img class="small-thumb" src="/books/NBK548114/table/Rosiglitazone.T2/?report=thumb" src-large="/books/NBK548114/table/Rosiglitazone.T2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Rosiglitazone.T2"><a href="/books/NBK548114/table/Rosiglitazone.T2/?report=objectonly" target="object" rid-ob="figobRosiglitazoneT2">Table</a></h4></div></div></div><div id="Rosiglitazone.Comment"><h4>Comment</h4><p>Acute hepatocellular injury without signs of allergy (fever, eosinophilia and rash) developed within 1 to 2 weeks of starting rosiglitazone. While the pattern of liver enzyme elevations and severity of injury resembles that described with troglitazone, the short latency is atypical for the other thiazolidinediones. Interestingly, the patient did not tolerate troglitazone in the past, although no liver tests were performed at the time. Thus, the rapid development of liver injury upon starting rosiglitazone may have been due to cross reactivity of the injury with troglitazone and a form of reexposure. The timing of onset and recovery make rosiglitazone a highly likely cause of this hepatic injury.</p></div></div></div><div id="Rosiglitazone.PRODUCT_INFORMATION"><h2 id="_Rosiglitazone_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Rosiglitazone.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Rosiglitazone – Avandia®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Hypoglycemic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rosiglitazone" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Rosiglitazone.CHEMICAL_FORMULA_AND_STRUC"><h2 id="_Rosiglitazone_CHEMICAL_FORMULA_AND_STRUC_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figRosiglitazoneT3"><a href="/books/NBK548114/table/Rosiglitazone.T3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figRosiglitazoneT3" rid-ob="figobRosiglitazoneT3"><img class="small-thumb" src="/books/NBK548114/table/Rosiglitazone.T3/?report=thumb" src-large="/books/NBK548114/table/Rosiglitazone.T3/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Rosiglitazone.T3"><a href="/books/NBK548114/table/Rosiglitazone.T3/?report=objectonly" target="object" rid-ob="figobRosiglitazoneT3">Table</a></h4></div></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548114_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">June 6, 2018</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Rosiglitazone. [Updated 2018 Jun 6].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Ropinirole/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Rosuvastatin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobRosiglitazoneT1"><div id="Rosiglitazone.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548114/table/Rosiglitazone.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Rosiglitazone.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Rosiglitazone (4 mg daily for 11 days)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=12)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">3+ (jaundice and hospitalization)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Latency:</td><td rowspan="1" colspan="1" style="vertical-align:top;">8 days to nausea and abdominal pain, 11 days to jaundice</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">2 months</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Bronchodilators, theophylline, prednisone, zafirlukast, acetaminophen (<2 g/day), and remotely repaglinide, metformin, sulfonylureas</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobRosiglitazoneT2"><div id="Rosiglitazone.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548114/table/Rosiglitazone.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Rosiglitazone.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">ALT (U/L)</th><th id="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Bilirubin (mg/dL)</th><th id="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">40</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 days</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1706</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">331</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">9.6</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Rosiglitazone stopped</td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">15 days</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 days</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1349</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">412</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">13.8</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">18 days</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 days</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1251</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">519</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">12.8</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Discharge</td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">24 days</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">558</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">486</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">12.1</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">31 days</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">133</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">274</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.9</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">9 weeks</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">41</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">165</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.3</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 weeks</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">38</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">144</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.8</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Rosiglitazone.T2_1_1_1_1 hd_h_Rosiglitazone.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><40</b>
|
|
</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><117</b>
|
|
</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Rosiglitazone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="boxed-text" id="figobRosiglitazoneBPI"><div id="Rosiglitazone.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Rosiglitazone – Avandia®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Hypoglycemic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rosiglitazone" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></article><article data-type="table-wrap" id="figobRosiglitazoneT3"><div id="Rosiglitazone.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548114/table/Rosiglitazone.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Rosiglitazone.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Rosiglitazone.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Rosiglitazone.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Rosiglitazone.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Rosiglitazone.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Rosiglitazone.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Rosiglitazone</td><td headers="hd_h_Rosiglitazone.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135040639" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">122320-73-4</a>
|
|
</td><td headers="hd_h_Rosiglitazone.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C18-H19-N3-O3-S</td><td headers="hd_h_Rosiglitazone.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548114/bin/Rosiglitazone_Structure.jpg" alt="Rosiglitazone chemical structure" /></div>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|